Page last updated: 2024-09-05

lenalidomide and Leukemia

lenalidomide has been researched along with Leukemia in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (40.00)	29.6817
2010's	3 (60.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Abdallah, AO; Bailey, C; Barlogie, B; Chauhan, N; Cottler-Fox, M; Crowley, J; Epstein, J; Heuck, CJ; Hoering, A; Johann, D; Muzaffar, J; Petty, N; Rosenthal, A; Sawyer, J; Sexton, R; Singh, Z; Usmani, SZ; van Rhee, F; Waheed, S; Yaccoby, S	1
Moskowitz, AJ	1
Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A	1
Fiedler, W; Wellbrock, J	1
Dimopoulos, MA; Kastritis, E	1

Reviews

3 review(s) available for lenalidomide and Leukemia

Article	Year
[Novel medical treatment modalities in hematology]. Ugeskrift for laeger, 2008, Jun-09, Volume: 170, Issue:24 Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine	2008
Clinical experience with antiangiogenic therapy in leukemia. Current cancer drug targets, 2011, Volume: 11, Issue:9 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Humans; Indoles; Lenalidomide; Leukemia; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib; Thalidomide; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2011
The evolving role of lenalidomide in the treatment of hematologic malignancies. Expert opinion on pharmacotherapy, 2007, Volume: 8, Issue:4 Topics: Amyloidosis; Antineoplastic Agents; Hematologic Neoplasms; Humans; Lenalidomide; Leukemia; Myelodysplastic Syndromes; Thalidomide	2007

Other Studies

2 other study(ies) available for lenalidomide and Leukemia

Article	Year
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma. Blood, 2013, Jun-06, Volume: 121, Issue:23 Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Female; Follow-Up Studies; Humans; Incidence; Lenalidomide; Leukemia; Male; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Risk Factors; Thalidomide; Young Adult	2013
Lenalidomide in adult T-cell leukaemia-lymphoma. The Lancet. Haematology, 2016, Volume: 3, Issue:3 Topics: Adult; Antineoplastic Agents; Humans; Lenalidomide; Leukemia; Leukemia-Lymphoma, Adult T-Cell; T-Lymphocytes; Thalidomide; Treatment Outcome	2016

Article

Year

Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.

Blood, 2013, Jun-06, Volume: 121, Issue:23

Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Female; Follow-Up Studies; Humans; Incidence; Lenalidomide; Leukemia; Male; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Risk Factors; Thalidomide; Young Adult

2013

Lenalidomide in adult T-cell leukaemia-lymphoma.

The Lancet. Haematology, 2016, Volume: 3, Issue:3

Topics: Adult; Antineoplastic Agents; Humans; Lenalidomide; Leukemia; Leukemia-Lymphoma, Adult T-Cell; T-Lymphocytes; Thalidomide; Treatment Outcome

2016